PPH vs XPH

PPHAVanEck Pharmaceutical ETF

XPHBState Street SPDR S&P Pharmaceuticals ETF

In short

PPH About two dozen US-listed drugmakers in one ticker, tracking the MVIS US Listed Pharmaceutical 25 Index since 2011. VanEck charges well under the pharma-fund median to run it.

XPH Most pharma funds are a mega-cap sandwich. XPH equal-weights instead, so a small-cap drugmaker gets roughly the same say as an industry giant, across about 60 names, for 0.35% a year.

Stated mandate

PPH The fund seeks to track, before fees and expenses, the performance of the MVIS US Listed Pharmaceutical 25 Index, which covers companies involved in pharmaceutical research and development, production, marketing, and sales.

XPH The fund seeks to provide exposure to the pharmaceuticals segment of the S&P TMI.

Why people hold it

• PPH Costs 0.36% a year against a 0.57% median for pharma ETFs, undercutting peers like PJP and FTXH.
• Focused by design: the index tracks US-listed pharmaceutical companies (research, production, marketing, sales) rather than the whole health care aisle.vaneck.com
• Trading since 2011, one of the veterans of the pharma shelf, and it sits in the top quartile of its peer group on our review.
• Pays out quarterly, and it is a moderately traded fund, so getting in and out is usually straightforward.

• XPH Modified equal weighting with quarterly rebalances: the index trims what has run and keeps real room for small and mid-cap drugmakers, not just the household names.ssga.com
• At 0.35%, the cheapest sticker in its pharma peer group and well under the group median of 0.57% (PPH 0.36%, IHE 0.37%, PJP 0.57%, FTXH 0.60%).
• Pure pharma, not a health care grab bag: it draws only from the pharmaceuticals segment of the S&P Total Market Index. No insurers, hospitals or device makers.ssga.com
• Running since 2006 under a single index rulebook, with assets in the mid-size range and about 60 holdings behind it.

Worth knowing

• PPH Around 26 holdings. One company's trial result or patent cliff carries real weight in a basket this tight.
• Single-sector health care exposure: drug pricing politics and regulation land on the whole basket at once, with nothing else to cushion it.
• The fee edge over the category is real, but XPH sits at 0.35%, so cost alone is not what separates these two.

• XPH Equal weighting pulls the portfolio down the cap ladder, where trial results and FDA decisions can swing a single stock hard. Expect a bumpier ride than mega-cap pharma.ssga.com
• One industry, one country. Drug pricing rules and patent cliffs hit the whole basket at once.
• Moderately traded rather than a volume monster, so spreads can widen. Limit orders are the usual answer.

Full PPH profile⁠

Full XPH profile⁠